(CSE:XPHY / OTC:XPHYF / FSE:4XT)
- Completed Successful SARS-CoV-2 RT-PCR Diagnostic Test Kit Validation
- Secured Exclusive Psychedelic Drug Development Agreement
- Appointed European Healthcare Executive to Board of Director
- Engaged German Partner for Development of Psilocybin API Production
- Announced Update on Contract Drug Delivery Program
- Announced Update on Oral Thin Film Drug Delivery Program
- Provided Update on Parkinson’s Transdermal Patch
Three Xphyto Divisions:
1. Vektor Pharma TF: World-class thin film drug delivery platforms for transdermal and oral dissolvable dosage forms
2. 3a-Diagnostics: Rapid, low-cost screening tests for pandemic and dental health applications
3. Xphyto Laboratories Inc.: Development of industrial production processes for emerging active pharmaceutical ingredients, including psychedelics and cannabinoid isolates
1. Vektor Pharma TF GmbH – Drug Delivery
100% owned XPhyto subsidiary
Global leader in design, testing and manufacture of therapeutic film drug delivery systems
- Major pharma clients – past, present and future
- Focused and nimble team – rapid turnaround on new opportunities
Versatile platform technology
- Transdermal patches (TDS) – slow and steady release
- Oral dissolvable film (ODF) sublingual strips – instant bioavailability
EU GMP facilities in Baden-Württemberg, Germany
Holder of numerous German narcotics import and manufacturing licences
XPhyto Drug Development Pipeline – Stage 1 & 2
- Platform technology
- Scalable product development pipeline
- High-growth and new API opportunities
- Neurological indications
- Generic and hybrid-generic drug formulations
2. 3a-Diagnostics GmbH – Rapid Testing
XPhyto has an exclusive development, technology purchase and licence agreement
Specializing in the development, production, and marketing of low-cost point-of-care screening test systems:
- COVID-19 rapid PCR Kit
- COVID-19 disposable ultra-rapid test
- Oral biosensors for the instant detection of bacterial and viral pathogens
- Influenza A, H1N1 (swine flu), H5N1 (avian flu), Strep A, stomatitis, periimplantitis and periodontitis
- Biosensor screening platform for high-throughput for identification of new biosensor targets for new biosensor products
Development partially funded by grants from the German Federal Ministry of Education and Research (BMBF)
Lead Products:
COVID-19 rapid PCR Kit
- Diagnostic level accuracy, rapid results (<25 minutes), minimal lab equipment
- European commercial approval and product launch planned for Q1 2021
Periimplantitis oral biosensor
- For the early detection of infection associated with dental implants
- Biosensor releases an extremely bitter compound when exposed to the causative pathogenic bacteria
- European commercial approval and product launch planned for Q4 2021
3. XPhyto Laboratories Inc. & Vektor Pharma TF GmbH – Psychedelics
100% owned XPhyto subsidiaries
Exclusive agreements with leading German and Canadian universities
Germany:
- Development of psychedelic drug formulations – sublingual and transdermal
- Development of biotechnology process for industrial scale production of psilocybin API
- 12-month development program commenced Q3 2020
Canada:
- Certified analytical testing for cannabis and psychedelics
- Development programs for industrial scale and EU GMP production of mescaline, MDMA, DMT, and cannabinoid isolates
- Novel psychedelic drug formulations
Clinical validation planned for Germany and Canada
Hub On AGORACOM / Corporate Profile
Tags: Bioscience, covid19, Delivery, Drug, Healthcare, Opportunities, Oral, Rapid, Testing